Characteristics of lipid profiles and lipid control in patients with diabetes in a tertiary hospital in Southwest China: an observational study based on electronic medical records
Tóm tắt
Diabetes is often accompanied by dyslipidemia. Lipid control is very important in the management of diabetes. There are limited real world data on the lipid control in diabetic inpatients in southwest China. An observational study was conducted to assess the characteristics of lipid profiles and lipid control. Diabetic patients from February 2009 to December 2013 at West China Hospital of Sichuan University were identified. A total of 56,784 inpatients were included and 85.9% of them had at least one lipid panel. The proportions of inpatients with optimal low-density lipoprotein cholesterol (LDL-C) level (< 2.59 mmol/L), optimal triglyceride (TG) level (< 1.70 mmol/L), optimal high-density lipoprotein cholesterol (HDL-C) level (men ≥1.04 mmol/L; women ≥1.30 mmol/L) and optimal non-high-density lipoprotein cholesterol (non-HDL-C) level (< 3.37 mmol/L) were 61.1, 64.6, 49.9 and 64.5%, respectively. Only 23.1% of inpatients obtained optimal levels for all the above four lipid parameters. Of diabetic inpatients with ischemic heart disease, the proportions of inpatients with optimal LDL-C level (< 1.81 mmol/L), optimal TG level (< 1.70 mmol/L), optimal HDL-C level (men ≥1.04 mmol/L; women ≥1.30 mmol/L) and optimal non-HDL-C level (< 2.59 mmol/L) were 38.0, 66.3, 48.1 and 48.7%, respectively. Of diabetic inpatients with cerebrovascular disease, the proportions were 28.3, 64.8, 49.9 and 38.1%, respectively. Older people and men were more likely to obtain optimal lipid levels. However, inpatients between 46 and 64 years were least likely to obtain optimal LDL-C levels. The lipid control of diabetic inpatients in southwest China is worrisome. Individualized strategies of lipid management should be taken to bridge the gap between the recommendations of clinical guidelines and the real situation of clinical practice.
Tài liệu tham khảo
International Diabetes Federation. Diabetes Atlas (sixth edition). 2013.
Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59.
Zhang P, Zhang XZ, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:293–301.
Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2197–223.
Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs. 2013;73:327–39.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106:3143–421.
Haffner SM. American Diabetes Association (ADA). Management of Dyslipidemia in adults with diabetes. Diabetes Care. 2003;26:S83–6.
Wang SY, Hsieh MC, Tu ST, et al. New Frontiers in the treatment of diabetic dyslipidemia. Rev Diabet Stud. 2013;10:204–12.
Li S, Yu C, Li Y, et al.. Study design and baseline characteristics of inpatients with diabetes mellitus in a tertiary hospital in China: a database study based on electronic medical records. J Evid Based Med . 2018. https://doi.org/10.1111/jebm.12291.
American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37:S14–80.
Jacobs MJ, Kleisli T, Pio JR, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70:263–9.
Spinler SA, Cziraky MJ, Willey VJ, et al. Frequency of attainment of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol goals in cardiovascular clinical practice (from the National Cardiovascular Data Registry PINNACLE registry). Am J Cardiol. 2015;116:547–53.
Mithal A, Majhi D, Shunmugavelu M, et al. Prevalence of dyslipidemia in adult Indian diabetic patients: a cross sectional study (SOLID). Indian J Endocrinol Metab. 2014;18:642–7.
Kennedy AG, MacLean CD, Littenberg B, et al. The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 2005;28:1029–34.
Baigent C, Keech A, Kearney PM, et al. Cholesterol treatment Trialists’ (CTT) collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med. 2001;161:1413–9.
Zhang X, Ji L, Ran X, et al. Gender disparities in lipid goal attainment among type 2 diabetes outpatients with coronary heart disease: results from the CCMR-3B study. Sci Rep. 2017;7:12648.
Li X, Xu Y, Li J, et al. The gender differences in baseline characteristics and statin intervention among outpatients with coronary heart disease in China: the China cholesterol education program. Clin Cardiol. 2009;32:308–14.
Karalis DG, Wild RA, Maki KC, et al. Gender differences in side effects and attitudes regarding statin use in the understanding statin use in America and gaps in patient education (usage) study. J Clin Lipidol. 2016;10:833–41.
Farbakhsh K, Kasiske BL. Dyslipidemias in patients who have chronic kidney disease. Med Clin North Am. 2005;89:689–99.
Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19:1045–52.